Bruker Corp designs & manufactures proprietary life science & materials research systems & associated products that serve multiple customers in life science research, pharmaceuticals, applied markets, nanotechnology, cell biology, clinical research, microbiology & in-vitro diagnostics. BSI Life Science reports under two groups: Bruker BioSpin Group & Bruker CALID Group. The Bruker BioSpin comprises the Bruker Magnetic Resonance & Preclinical Imaging divisions, which designs, manufactures & distributes enabling life science tools based on the magnetic resonance technology. The Bruker CALID comprises the Bruker Daltonics & primarily designs, manufactures & distributes life-science mass spectrometry instruments that can be integrated with other sample preparation or chromatography instruments. BSI Nano designs, manufactures & distributes advanced X-ray instruments to determine the characteristics of matter & the three-dimensional structure of molecules....
+See More2024-05-05 10:31:00 Sunday ET
Stock Synopsis: Pharmaceutical post-pandemic patent development cycle In terms of stock market valuation, the major pharmaceutical sector remains at its
2019-05-15 12:32:00 Wednesday ET
The May administration needs to seek a fresh fallback option for Halloween Brexit. After the House of Commons rejects Brexit proposals from the May administ
2022-03-25 09:34:00 Friday ET
Corporate cash management The empirical corporate finance literature suggests four primary motives for firms to hold cash. These motives include the tra
2019-05-09 10:28:00 Thursday ET
President Trump ramps up 25% tariffs on $200 billion Chinese imports soon after China backtracks on the Sino-American trade agreement. U.S. trade envoy Robe
2019-07-23 09:22:00 Tuesday ET
Harvard economic platform researcher Dipayan Ghosh proposes some alternative solutions to breaking up tech titans such as Facebook, Google, Apple, and Amazo
2016-10-19 00:00:00 Wednesday ET
India's equivalent to Warren Buffett in America, Rakesh Jhunjhunwala, offers several key lessons for stock market investors: When the press o